These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 8732269

  • 1. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K, Tada S, Matsumoto M, Ohmori J, Tasaki Y, Nomura T, Usuda S, Yamaguchi T.
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [Abstract] [Full Text] [Related]

  • 2. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T.
    J Med Chem; 1996 Jul 05; 39(14):2764-72. PubMed ID: 8709107
    [Abstract] [Full Text] [Related]

  • 3. YM-50001: a novel, potent and selective dopamine D4 receptor antagonist.
    Hidaka K, Tada S, Matsumoto M, Ohmori J, Maeno K, Yamaguchi T.
    Neuroreport; 1996 Nov 04; 7(15-17):2543-6. PubMed ID: 8981420
    [Abstract] [Full Text] [Related]

  • 4. Functional and autoradiographic characterization of dopamine D2-like receptors in the guinea pig heart.
    Gómez Mde J, Rousseau G, Nadeau R, Berra R, Flores G, Suárez J.
    Can J Physiol Pharmacol; 2002 Jun 04; 80(6):578-87. PubMed ID: 12117307
    [Abstract] [Full Text] [Related]

  • 5. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
    Tallman JF, Primus RJ, Brodbeck R, Cornfield L, Meade R, Woodruff K, Ross P, Thurkauf A, Gallager DW.
    J Pharmacol Exp Ther; 1997 Aug 04; 282(2):1011-9. PubMed ID: 9262370
    [Abstract] [Full Text] [Related]

  • 6. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.
    J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168
    [Abstract] [Full Text] [Related]

  • 7. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A.
    J Pharmacol Exp Ther; 1995 Dec 10; 275(3):1239-46. PubMed ID: 8531087
    [Abstract] [Full Text] [Related]

  • 8. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul 10; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 9. Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626.
    Bowery BJ, Razzaque Z, Emms F, Patel S, Freedman S, Bristow L, Kulagowski J, Seabrook GR.
    Br J Pharmacol; 1996 Dec 10; 119(7):1491-7. PubMed ID: 8968560
    [Abstract] [Full Text] [Related]

  • 10. Syntheses and pharmacological evaluation of two potent antagonists for dopamine D4 receptors: [11C]YM-50001 and N-[2-[4-(4-Chlorophenyl)-piperizin-1-yl]ethyl]-3-[11C]methoxybenzamide.
    Zhang MR, Haradahira T, Maeda J, Okauchi T, Kawabe K, Noguchi J, Kida T, Suzuki K, Suhara T.
    Nucl Med Biol; 2002 Feb 10; 29(2):233-41. PubMed ID: 11823129
    [Abstract] [Full Text] [Related]

  • 11. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors.
    Videbaek C, Toska K, Scheideler MA, Paulson OB, Moos Knudsen G.
    Synapse; 2000 Dec 01; 38(3):338-42. PubMed ID: 11020237
    [Abstract] [Full Text] [Related]

  • 12. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
    Patel S, Patel S, Marwood R, Emms F, Marston D, Leeson PD, Curtis NR, Kulagowski JJ, Freedman SB.
    Mol Pharmacol; 1996 Dec 01; 50(6):1658-64. PubMed ID: 8967990
    [Abstract] [Full Text] [Related]

  • 13. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW.
    J Pharmacol Exp Ther; 1995 Dec 01; 275(3):1355-66. PubMed ID: 8531103
    [Abstract] [Full Text] [Related]

  • 14. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S.
    J Pharmacol Exp Ther; 1995 Nov 01; 275(2):885-98. PubMed ID: 7473180
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC, Boyfield I, Brown AM, Stemp G, Middlemiss DN.
    Br J Pharmacol; 1999 Jul 01; 127(5):1135-44. PubMed ID: 10455259
    [Abstract] [Full Text] [Related]

  • 16. The discovery of PD 89211 and related compounds: selective dopamine D4 receptor antagonists.
    Pugsley TA, Shih YH, Whetzel SZ, Zoski K, Van Leeuwen D, Akunne H, Mackenzie R, Heffner TG, Wustrow D, Wise LD.
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb 01; 26(2):219-26. PubMed ID: 11817497
    [Abstract] [Full Text] [Related]

  • 17. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 01; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 18. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis.
    Whiting RL, Choppin A, Luehr G, Jasper JR.
    J Pharmacol Exp Ther; 2021 Oct 01; 379(1):85-95. PubMed ID: 34253646
    [Abstract] [Full Text] [Related]

  • 19. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Agai-Csongor E, Domány G, Szombathelyi Z.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov 01; 378(5):515-28. PubMed ID: 18551280
    [Abstract] [Full Text] [Related]

  • 20. Characterization of [125I]S(-)5-OH-PIPAT binding to dopamine D2-like receptors expressed in cell lines.
    Vessotskie JM, Kung MP, Chumpradit S, Kung HF.
    Neuropharmacology; 1997 Jul 01; 36(7):999-1007. PubMed ID: 9257944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.